Use: Labeled indications
SmPC 4.1 Therapeutic indications EU SmPC (EMA)
Menveo is indicated for active immunization of children (from 2 years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W-135 and Y, to prevent invasive disease. The use of this vaccine should be in accordance with official recommendations.
Contraindications
SmPC 4.3 Contraindications EU SmPC (EMA)
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1, or diphtheria toxoid (CRM197), or a life-threatening reaction after previous administration of a vaccine containing similar components (see section 4.4).
As with other vaccines, Menveo should be postponed in individuals suffering from an acute severe febrile illness. The presence of a minor infection is not a contraindication.
Dosing: Adult
SmPC 4.2 Posology and method of administration EU SmPC (EMA)
Posology
Children (from 2 years of age), adolescents and adults
Menveo should be administered as a single dose (0.5 mL). To ensure optimal antibody levels against all vaccine serogroups, the primary vaccination schedule with Menveo should be completed one month prior to risk of exposure to Neisseria meningitidis groups A, C, W-135 and Y. Bactericidal antibodies (hSBA ≥ 1:8) were observed in at least 64% of subjects at 1 week post vaccination (see section 5.1 for immunogenicity data per individual serogroups).
Older adults and elderly
There are limited data in older adults (aged 56-65 years) and there are no data in elderly (aged > 65 years).
Booster vaccination
Long-term antibody persistence data following vaccination with Menveo are available up to 5 years after vaccination (see section 4.4 and 5.1).
Menveo may be given as a booster dose in subjects who have previously received primary vaccination with Menveo, other conjugated meningococcal vaccine or meningococcal unconjugated polysaccharide vaccine. The need for and timing of a booster dose in subjects previously vaccinated with Menveo is to be defined based on national recommendations.
Paediatric population (under 2 years of age)
The safety and efficacy of Menveo in children under 2 years of age has not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.
Method of administration
Menveo is given as an intramuscular injection, preferably into the deltoid muscle. It must not be administered intravascularly, subcutaneously or intradermally.
Separate injection sites must be used if more than one vaccine is being administered at the same time.
For instructions on preparation of the medicinal product before administration, see section 6.6.
Dosing: Altered kidney function
The EU SmPC (EMA) for this generic has no separate kidney-specific text. See SmPC 4.2 and 5.2 below, and the Philippine package insert.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric population (SmPC 4.2) EU SmPC (EMA)
Children (from 2 years of age), adolescents and adults
Menveo should be administered as a single dose (0.5 mL). To ensure optimal antibody levels against all vaccine serogroups, the primary vaccination schedule with Menveo should be completed one month prior to risk of exposure to Neisseria meningitidis groups A, C, W-135 and Y. Bactericidal antibodies (hSBA ≥ 1:8) were observed in at least 64% of subjects at 1 week post vaccination (see section 5.1 for immunogenicity data per individual serogroups).
Paediatric population (under 2 years of age)
The safety and efficacy of Menveo in children under 2 years of age has not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.
Dosing: Older adult
Older adults (SmPC 4.2) EU SmPC (EMA)
Older adults and elderly
There are limited data in older adults (aged 56-65 years) and there are no data in elderly (aged > 65 years).
Dosage forms
Registered products in the Philippines
1 product registered with the Food and Drug Administration (FDA) Philippines list C + Meningococcal group a + W-135 + Y conjugate vaccine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
MenquadfiMeningococcal Group A, C, W-135 and Y Conjugate Vaccine | Formulation: Each dose (0.5 mL) contains: Neisseria meningitidis group A polysaccharide* .... 10 mcg Neisseria meningitidis group C polysaccharide* .... 10 mcg Neisseria meningitidis group Y polysaccharide* .... 10 mcg Neisseria meningitidis group W-135 polysaccharide* .... 10 mcg *Conjugated to Tetanus Toxoid carrier protein... 55 mcg** **Tetanus Toxoid quantity is approximate and dependent on the polysaccharide to protein ratio for the conjugates in each formulation Solution for Injection (IM)Single dose. 0.5 mL in 2 mL USP Type I glass vial with gray chlorobutyl rubber stopper sealed with aluminum and black plastic flip-off cap (Box of 1's and 5's) | Rx | Sanofi PasteurU.S.A | Zuellig Pharma CorporationImporter: Sanofi Pasteur, Inc. | BR-1388 | Mar 4, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
SmPC 4.4 Special warnings and precautions for use EU SmPC (EMA)
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Hypersensitivity and anaphylaxis
Before the injection of any vaccine, the person responsible for administration must take all precautions known for the prevention of allergic or any other reactions including thorough medical history and current health status. As with all injectable vaccines, appropriate medical treatment and supervision must always be readily available in case of a rare anaphylactic event following administration of the vaccine.
Anxiety-related reactions
Anxiety‐related reactions, including vasovagal reactions (syncope), hyperventilation or stress‐related reactions may occur in association with vaccination as a psychogenic response to the needle injection (see section 4.8). It is important that procedures are in place to avoid injury from fainting.
Menveo should under no circumstances be administered intravascularly.
Limitations of effectiveness
Menveo will not protect against infections caused by any other serogroups of N. meningitidis not present in the vaccine.
As with any vaccine, a protective immune response may not be elicited in all vaccinees (see section 5.1).
Studies with Menveo have shown a waning of serum bactericidal antibody titers against serogroup A when using human complement in the assay (hSBA) (see section 5.1). The clinical relevance of the waning of hSBA serogroup A antibody titers is unknown. If an individual is expected to be at particular risk of exposure to Men-A and received a dose of Menveo more than approximately one year previously, consideration may be given to administering a booster dose.
There are no data on the applicability of the vaccine for post-exposure prophylaxis.
Immunocompromised individuals
In immunocompromised individuals, vaccination may not result in an appropriate protective antibody response. While Human Immunodeficiency Virus (HIV) infection is not a contraindication, Menveo has not been specifically evaluated in immunocompromised people. Individuals with complement deficiencies and individuals with functional or anatomical asplenia may not mount an immune response to meningococcal group A, C, W-135 and Y conjugate vaccines.
Individuals with familial complement deficiencies (for example, C3 or C5 deficiencies) and individuals receiving treatments that inhibit terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis group A, C, W-135 and Y, even if they develop antibodies following vaccination with Menveo.
Thrombocytopenia and coagulation disorders
Menveo has not been evaluated in persons with thrombocytopenia, bleeding disorders or that are receiving anticoagulant therapy, because of the risk of haematoma. The risk-benefit ratio for persons at risk of haematoma following intramuscular injection must be evaluated by health care professionals.
Excipient with known effect
Sodium
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.
Drug interactions
SmPC 4.5 Interaction with other medicinal products and other forms of interaction EU SmPC (EMA)
Menveo can be given concomitantly with any of the following vaccines: monovalent and combined hepatitis A and B, yellow fever, typhoid fever (Vi polysaccharide), Japanese encephalitis, rabies and meningococcal group B (Bexsero).
In adolescents (11 to 18 years of age), Menveo has been evaluated in two co-administration studies with either Tetanus, Reduced Diphtheria and Acellular Pertussis Vaccine, adsorbed (Tdap) alone or Tdap and Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant (HPV), both of which support the co-administration of the vaccines.
The administration of Menveo one month after Tdap resulted in statistically significantly lower serogroup W-135 seroresponses. Since there was no direct impact on the seroprotection rate, the clinical consequences are presently unknown. There was evidence of some suppression of antibody
response to two of the three pertussis antigens. The clinical relevance of this observation is unknown. After vaccination, over 97% of subjects had detectable pertussis titers to all three pertussis antigens.
For children 2 to 10 years of age, no data are available for evaluating safety and immunogenicity of other childhood vaccines when administered concomitantly with Menveo.
Concomitant administration of Menveo with vaccines other than those listed above has not been studied. Concomitant vaccines should always be administered at separate injection sites and preferably contralateral. It should be checked if the adverse reactions may be intensified by any co-administration.
If a vaccine recipient is undergoing immunosuppressant treatment, the immunological response may be diminished.
Adverse reactions
SmPC 4.8 Undesirable effects EU SmPC (EMA)
Summary of the safety profile
The most frequently reported adverse reactions within 7 days after vaccination with a single dose of Menveo alone in individuals aged 2 years and above were injection-site pain (42.7%), headache (26.4%), injection-site erythema ≤ 50 mm (18.1%), malaise (17.3%), injection-site induration ≤ 50 mm (15.1%), myalgia (13.5%) and irritability (11.3%) in children aged 2 to 10 years. These adverse reactions were mostly mild or moderate in intensity.
Tabulated list of adverse reactions
The safety of Menveo in individuals aged 2 years and older was evaluated in 11 randomized studies. 12 775 individuals were included in the safety analyses, of these, 3 334 participants aged 2 to 10 years and 9 441 participants aged 11 to 65 years were exposed to Menveo in completed clinical studies.
The following adverse reactions, as listed in Table 1 below, have been identified in clinical studies conducted with Menveo when given to individuals 2 years and older, and during post-marketing surveillance.
Adverse reactions are listed below by MedDRA system organ class and frequency. Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.
Very common (≥ 1/10)
Common (≥ 1/100 to < 1/10)
Uncommon (≥ 1/1 000 to < 1/100)
Rare (≥ 1/10 000 to < 1/1 000)
Very rare (< 1/10 000)
Not known (cannot be estimated from the available data)
Table 1: Adverse reactions
System organ class Frequency Adverse reactions
Blood and lymphatic system
Uncommon Lymphadenopathy1
disorders
Immune system disorders Uncommon Hypersensitivity1
Not known Anaphylaxis1
Metabolism and nutrition
Common Eating disorder2
disorders
Nervous system disorders Very common Headache
Common Sleepiness2
Uncommon Syncope1, dizziness3
Very rare Tonic convulsion1, febrile convulsion1
Ear and labyrinth disorders Uncommon Vertigo1
Gastrointestinal disorders Common Vomiting2, diarrhoea2, nausea
Skin and subcutaneous tissue
Common Rash
disorders
Musculoskeletal and Very common Myalgia
connective tissue disorders Common Arthralgia
General disorders and Irritability2, malaise, injection site pain, injection
administration site conditions Very common site erythema (≤ 50 mm), injection site induration
(≤ 50 mm)
Fever (≥ 38 °C), chills, injection site erythema
Common
(> 50 mm), injection site induration (> 50 mm)
Uncommon Injection site pruritus, injection site swelling1
injection site cellulitis1, extensive swelling of the
Very rare
injected limb1
Adverse reaction reported during post-marketing surveillance
Reported in children 2 to 10 years of age
Reported in individuals 11 to 65 years of ageReporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Pregnancy considerations
SmPC 4.6 Fertility, pregnancy and lactation EU SmPC (EMA)
Insufficient clinical data on exposed pregnancies are available.
In non-clinical studies, Menveo had no direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Considering the severity of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y, pregnancy should not preclude vaccination when the risk of exposure is clearly defined.
Although insufficient clinical data on the use of Menveo during breast-feeding are available, it is unlikely that secreted antibodies in milk would be harmful when ingested by a breastfed infant. Therefore, Menveo may be used during breast feeding.
Breastfeeding considerations
Breastfeeding is covered in SmPC 4.6 Fertility, pregnancy and lactation, under Pregnancy considerations above.
Overdose
SmPC 4.9 Overdose EU SmPC (EMA)
No case of overdose has been reported.
Mechanism of action
SmPC 5.1 Pharmacodynamic properties EU SmPC (EMA)
Pharmacotherapeutic group: Meningococcal vaccines, ATC code: J07AH08
Immunogenicity of Menveo liquid
Immunogenicity of Menveo liquid, as evaluated in a phase 2b observer-blind, randomised, multicentre, controlled clinical trial in subjects aged 10 to 40 years that assessed the non-inferiority for MenA of Menveo liquid (for the product aged 24 and 30 months) to Menveo lyophilised/liquid, is presented in Table 2.
Non-inferiority of Menveo liquid to Menveo lyophilised/liquid was demonstrated for MenA as per the 2 co-primary study endpoints (between groups ratio of geometric mean titers (GMTs) at 1-month post vaccination with formulation aged 24 and 30 months).
Table 2: Serum bactericidal antibody responses 1 month after vaccination in subjects aged 10-40 years receiving Menveo liquid or Menveo lyophilised/liquid formulation
Study Menveo Menveo
(Menveo liquid / liquid minus
Menveo Menveo
liquid Endpoint by Menveo Menveo
liquid (95% lyophilised/liqu
product Serogroup lyophilised/li lyophilised/li
CI) id (95% CI)
age) quid quid (95%
(95% CI) CI)
V59_78 A N = 363 N = 373
(24 386.66
months)** 318.34 1.21
GMT (319.47, -
(264.14, 383.67) (0.94, 1.57)*
467.97)
93.65 92.19
1.46
% hSBA ≥ 1:8 (90.70, 95.89) (89.03, 94.67) -
(-2.24, 5.22)
N = 378 N = 384
C N = 385 N = 377
143.48
171.74 0.84
GMT (110.49, -
(131.74, 223.87) (0.58, 1.19)
186.30)
77.58 78.01
-0.43
% hSBA ≥ 1:8 (73.10, 81.63) (73.52, 82.06) -
(-6.32, 5.46)
N = 388 N = 382
W-135 N = 372 N = 388
62.63 66.37 0.94
GMT -
(50.99, 76.92) (54.26, 81.18) (0.72, 1.24)
79.43 80.87
-1.43
% hSBA ≥ 1:8 (75.07, 83.34) (76.62, 84.64) -
(-7.05, 4.18)
N = 389 N = 392
Y N = 379 N = 390
115.66 106.47 1.09
GMT -
(94.13, 142.13) (86.93, 130.42) (0.82, 1.44)
87.50 85.46
2.04
% hSBA ≥ 1:8 (83.77, 90.64) (81.57, 88.80) -
(-2.81, 6.90)
N = 384 N = 392
V59_78
A N = 356 N = 349
(30
months) 387.06
*** 348.89 1.11
GMT (322.72, -
(290.09, 419.61) (0.87, 1.42)*
464.24)
93.37 94.01
-0.64
% hSBA ≥ 1:8 (90.37, 95.66) (91.06, 96.21) -
(-4.24, 2.96)
N = 377 N = 367
C N = 376 N = 377
256.70
226.09 1.14
GMT (195.29, -
(171.62, 297.85) (0.79, 1.64)
337.41)
84.17 82.85
1.32
% hSBA ≥ 1:8 (80.10, 87.70) (78.67, 86.51) -
(-3.99, 6.64)
N = 379 N = 379
W-135 N = 374 N = 366
83.23 75.42 1.10
GMT -
(68.19, 101.60) (61.56, 92.41) (0.84, 1.45)
85.86 81.77
4.09
% hSBA ≥ 1:8 (82.00, 89.17) (77.54, 85.50) -
(-1.11, 9.33)
N = 389 N = 384
Y N = 386 N = 377
112.38 117.56 0.96
GMT -
(91.56, 137.92) (95.39, 144.89) (0.72, 1.26)
88.04 87.56
0.48
% hSBA ≥ 1:8 (84.42, 91.08) (83.85, 90.69) -
(-4.16, 5.13)
N = 393 N = 386
* Non-inferiority criterion met (the lower limit of the two-sided 95% CI > 0.5 for the between groups ratio of GMTs at
Day 29 [Menveo liquid / Menveo lyophilised/liquid]).
** refers to Part 1 of study V59_78, in which the Menveo liquid aged for 24 months was used.
*** refers to Part 2 of study V59_78, in which the Menveo liquid aged for 30 months was used.Immunogenicity of Menveo lyophilised/liquid
The efficacy of Menveo has been inferred by measuring the production of serogroup-specific anti-capsular antibodies with bactericidal activity. Serum bactericidal activity (SBA) was measured using human serum as the source of exogenous complement (hSBA). The hSBA was the original correlate of protection against meningococcal disease.
Immunogenicity was evaluated in randomised, multicenter, active controlled clinical trials that enrolled children (2-10 years of age), adolescents (11-18 years of age), adults (19-55 years of age) and older adults (56-65 years of age).
Immunogenicity in children 2 to 10 years of age
In the pivotal study V59P20 immunogenicity of Menveo was compared to ACWY-D; 1 170 children were vaccinated with Menveo and 1 161 received the comparator vaccine in the per protocol populations. In two supportive studies V59P8 and V59P10 immunogenicity of Menveo was compared to ACWY-PS.
In the pivotal, randomised, observer-blind study V59P20, in which participants were stratified by age (2 through 5 years and 6 through 10 years), the immunogenicity of a single dose of Menveo one month post vaccination was compared with the single dose of ACWY-D. Immunogenicity results one month after Menveo vaccination among subjects aged 2-5 years and 6-10 years are summarised below in Table 3.
Table 3: Serum bactericidal antibody responses following Menveo one month after vaccination among subjects aged 2-5 years and 6-10 years
2-5 years 6-10 years
Serogroup hSBA ≥ 1:8 hSBA GMTs hSBA ≥ 1:8 hSBA GMTs
(95% CI) (95% CI) (95% CI) (95% CI)
A N = 606 N = 606 N = 551 N = 551
72% 26 77% 35
(68, 75) (22, 30) (74, 81) (29, 42)
C N = 607 N = 607 N = 554 N = 554
68% 18 77% 36
(64, 72) (15, 20) (73, 80) (29, 45)
W-135 N = 594 N = 594 N = 542 N = 542
90% 43 91% 61
(87, 92) (38, 50) (88, 93) (52, 72)
Y N = 593 N = 593 N = 545 N = 545
76% 24 79% 34
(72, 79) (20, 28) (76, 83) (28, 41)In another randomised, observer-blind study (V59P8) US children were immunized with a single dose of either Menveo (N = 284) or ACWY-PS (N = 285). In the children 2-10 years of age, as well as in each age strata (2-5 and 6-10 years of age), immune response as measured by percentage of subjects with seroresponse, hSBA ≥ 1:8 and GMTs were not only non-inferior to comparator vaccine ACWY-PS, but all were statistically higher than the comparator for all serogroups and all immune measurements at 1 month post vaccination. At 1 year post vaccination, Menveo continued to be statistically higher than ACWY-PS for serogroups A, W-135 and Y, as measured by percentage of subjects with hSBA ≥ 1:8 and GMTs. Menveo was non-inferior on these endpoints for serogroup C (Table 4). The clinical relevance of higher post vaccination immune responses is not known.
Table 4: Immunogenicity of one dose of Menveo or ACWY-PS in subjects 2 through 10 years of age, measured at one month and twelve months post vaccination
1 month post vaccination 12 months post vaccination
Sero hSBA ≥ 1:8 hSBA GMTs hSBA ≥ 1:8 hSBA GMTs
grou (95% CI) (95% CI) (95% CI) (95% CI)
p ACWY ACWY- ACWY
Menveo Menveo Menveo Menveo ACWY-PS
-PS PS -PS
A N = 280 N = 281 N = 280 N = 281 N = 253 N = 238 N = 253 N = 238
6.31 3.88
79% 37% 36 23% 13% 3
(5.21, 7.6 (3.39, 4.4
(74, 84) (31, 43) (30, 44) (18, 29) (9, 18) (2.61, 3.44)
4) 4)
C N = 281 N = 283 N = 281 N = 283 N = 252 N = 240 N = 252 N = 240
73% 54% 26 15 53% 44% 11 9.02
(68, 78) (48, 60) (21, 34) (12, 20) (47, 59) (38, 51) (8.64, 13) (7.23, 11)
W-
N = 279 N = 282 N = 279 N = 282 N = 249 N = 237 N = 249 N = 237
92% 66% 60 14 90% 45% 42 7.57
(88, 95) (60, 71) (50, 71) (12, 17) (86, 94) (38, 51) (35, 50) (6.33, 9.07)
Y N = 280 N = 282 N = 280 N = 282 N = 250 N = 239 N = 250 N = 239
88% 53% 54 11 77% 32% 27 5.29
(83, 91) (47, 59) (44, 66) (9.29, 14) (71, 82) (26, 38) (22, 33) (4.34, 6.45)In a randomised, observer-blind study (V59P10) conducted in Argentina, children were immunized with a single dose of either Menveo (N = 949) or ACWY-PS (N = 551). Immunogenicity was assessed in a subset of 150 subjects in each vaccine group. The immune response observed in the children 2-10 years of age was very similar to those observed in the V59P8 study shown above:
immune response to Menveo at 1 month post vaccination, as measured by percentage of subjects with seroresponse, hSBA ≥ 1:8 and GMTs, was non-inferior to ACWY-PS.
A randomised, observer-blind study was conducted in children 12 to 59 months of age in Finland and Poland (V59P7). A total of 199 subjects 2-5 years of age were in the Menveo per protocol immunogenicity population and 81 subjects 3-5 years of age were in the ACWY-PS group.
At 1 month post-first vaccination, the percentages of subjects with hSBA ≥ 1:8 were consistently higher in the Menveo group for all four serogroups (63% vs 39%, 46% vs 39%, 78% vs 59%, and 65% vs 57% for Menveo as compared to ACWY-PS for serogroups A, C, W-135, and Y, respectively).
In a randomized, observer-blind study (V59_57) conducted in US, immunogenicity of a 2-dose series and a single dose of Menveo was compared in children 2 through 5 and 6 through 10 years of age (N = 715). At baseline, the percentage of subjects with hSBA ≥ 1:8 across the two age strata was 1%-5% for serogroup A, 13%-28% for serogroup C, 42%-64% for serogroup W-135, and 6%-19% for serogroup Y. At 1 month post last vaccination, the percentages of subjects with hSBA ≥ 1:8 in the 2-dose group and in the single dose group across the two age strata were: 90%-95% vs 76%-80% for serogroup A, 98%-99% vs 76%-87% for serogroup C, 99% vs 93%-96% for serogroup W-135, and 96% vs 65%-69% for serogroup Y. GMTs were higher in the 2-dose group than the single dose group at 1 month after vaccination in both age strata; however, this difference was less pronounced in the older age stratum.
At 1 year post last vaccination, the percentages of subjects with hSBA ≥ 1:8 after the 2-dose series and the single dose were both lower than at 1 month post vaccination (30% after the 2-dose series, 11%-20% after the single dose for serogroup A; 61%-81% and 41%-55% for serogroup C; 92%-94% and 90%-91% for serogroup W-135; 67%-75% and 57%-65% for serogroup Y). The differences between hSBA GMTs in the 2-dose and the single dose groups at 1 year after vaccination were lower than those seen at 1 month post vaccination.
The clinical benefit of a 2-dose vaccination series in children 2 through 10 years of age is not known.
Persistence of immune response and booster response in children 2 to 10 years of age
Antibody persistence at 5 years after primary vaccination was assessed in study V59P20E1, this was an extension of study V59P20. There was antibody persistence observed against serogroups C, W-135 and Y, with the percentages of subjects with hSBA ≥ 1:8 being 32% and 56% against serogroup C in subjects 2-5 and 6-10 years of age, respectively, 74% and 80% against serogroup W-135, and 48% and 53% against serogroup Y. GMTs were respectively 6.5 and 12 for serogroup C, 19 and 26 for serogroup W-135, and 8.13 and 10 for serogroup Y. For serogroup A, 14% and 22% of subjects 2-5 and 6-10 years of age, respectively, had hSBA ≥ 1:8 (GMTs 2.95 and 3.73). The children also received a booster dose of Menveo, 5 years after a single dose primary vaccination. All subjects in both age groups had hSBA ≥ 1:8 across all serogroups, with antibody titers several fold higher than seen after the primary vaccination (Table 5).
Table 5: Persistence of immune responses 5 years after primary vaccination with Menveo, and immune responses 1 month after a booster dose among subjects aged 2-5 years and 6-10 years at the time of primary vaccination
Serogr
2-5 years 6-10 years
oup
1 month after 1 month after
5 year persistence 5 year persistence
booster booster
hSBA hSBA hSBA hSBA hSBA hSBA hSBA hSBA
≥ 1:8 GMTs ≥ 1:8 GMTs ≥ 1:8 GMTs ≥ 1:8 GMTs
(95% (95% (95% (95% (95% (95% (95% (95%
CI) CI) CI) CI) CI) CI) CI) CI)
A N = 96 N = 96 N = 95 N = 95 N = 64 N = 64 N = 60 N = 60
2.95 100% 361 3.73 100% 350
14% 22%
(2.42, (96, (299, (2.74, (94, (265,
(7, 22) (13, 34)
3.61) 100) 436) 5.06) 100) 463)
C N = 96 N = 96 N = 94 N = 94 N = 64 N = 64 N = 60 N = 60
6.5 100% 498 12 100% 712
32% 56%
(4.75, (96, (406, (7.72, (94, (490,
(23, 43) (43, 69)
8.9) 100) 610) 19) 100) 1 036)
W-135 N = 96 N = 96 N = 95 N = 95 N = 64 N = 64 N = 60 N = 60
100% 1 534 100% 1 556
74% 19 80% 26
(96, (1 255, (94, (1 083,
(64, 82) (14, 25) (68, 89) (18, 38)
100) 1 873) 100) 2 237)
Y N = 96 N = 96 N = 94 N = 94 N = 64 N = 64 N = 59 N = 59
8.13 100% 1 693 10 100% 1 442
48% 53%
(6.11, (96, (1 360, (6.51, (94, (1 050,
(38, 58) (40, 66)
11) 100) 2 107) 16) 100) 1 979)Immunogenicity in individuals 11 years of age and above
In the pivotal study (V59P13), adolescents and adults received either a dose of Menveo (N = 2 649) or the comparator vaccine ACWY-D (N = 875). Sera were obtained both before vaccination and 1 month after vaccination.
In another study (V59P6) conducted in 524 adolescents, the immunogenicity of Menveo was compared to that of ACWY-PS.
Immunogenicity in adolescents
In the 11-18 year-old population of the pivotal study, V59P13, the immunogenicity of a single dose of Menveo one month post vaccination is compared with the ACWY-D. Immunogenicity results at one month after Menveo are summarised below in Table 6.
Table 6: Serum bactericidal antibody responses following Menveo one month after vaccination among subjects aged 11-18 years
GMT hSBA ≥ 1:8
Serogroup N
(95% CI) (95% CI)
A 1 075 29 (24, 35) 75% (73, 78)
C 1 396 50 (39, 65) 85% (83, 87)
W-135 1 024 87 (74, 102) 96% (95, 97)
Y 1 036 51 (42, 61) 88% (85, 90)In the subset of subjects aged 11-18 years who were seronegative at baseline (hSBA < 1:4), the proportion of subjects who achieved a hSBA ≥ 1:8 after a dose of Menveo were as follows: serogroup A 75% (780/1 039); serogroup C 80% (735/923); serogroup W-135 94% (570/609); serogroup Y 81% (510/630).
In the non-inferiority study, V59P6, immunogenicity was assessed among adolescents aged 11-17 years who had been randomised to receive either Menveo or ACWY-PS. Menveo was shown to be non-inferior to ACWY-PS vaccine for all four serogroups (A, C, W-135 and Y) based on seroresponse, proportions achieving hSBA ≥ 1:8, and GMTs (Table 7).
Table 7: Immunogenicity of one dose of Menveo or ACWY-PS in adolescents, measured at one month post vaccination
hSBA ≥ 1:8 hSBA GMTs
Serogroup (95% CI) (95% CI)
Menveo ACWY-PS Menveo ACWY-PS
A N = 140 N = 149 N = 140 N = 149
81% 41% 33 7.31
(74, 87) (33, 49) (25, 44) (5.64, 9.47)
C N = 140 N = 147 N = 140 N = 147
84% 61% 59 28
(77, 90) (53, 69) (39, 89) (19, 41)
W-135 N = 138 N = 141 N = 138 N = 141
91% 84% 48 28
(84, 95) (77, 89) (37, 62) (22, 36)
Y N = 139 N = 147 N = 139 N = 147
95% 82% 92 35
(90, 98) (75, 88) (68, 124) (27, 47)At one year post vaccination in these same subjects, compared with ACWY-PS, a higher proportion of subjects vaccinated with Menveo had hSBA ≥ 1:8 for serogroups C, W-135, and Y, with comparable levels for serogroup A. Similar findings were observed in the comparison of hSBA GMTs.
Persistence of immune response and booster response in adolescents
In study V59P13E1, the persistence of immune responses against serogroups A, C, W-135 and Y was assessed at 21 months, 3 years and 5 years post primary vaccination among subjects aged 11-18 years at the time of vaccination. The percentages of subjects with hSBA ≥ 1:8 remained constant against serogroups C, W-135, and Y from 21 months to 5 years post vaccination in the Menveo group and decreased slightly over time against serogroup A (Table 8). At 5 years after primary vaccination, there
were significantly higher percentages of subjects with hSBA ≥ 1:8 in the Menveo group than in the vaccine-naive control subjects against all the four serogroups.
Table 8: Persistence of immune responses approximately 21 months, 3 years and 5 years after vaccination with Menveo (subjects were aged 11-18 years at the time of vaccination)
Percentages of subjects with
hSBA GMTs
Serogroup Timepoint hSBA ≥ 1:8
Menveo Menveo
N = 100 N = 100
45 6.57 (4.77-9.05)
21 months
(35, 55)
A 38 5.63 (3.97-7.99)
3 years
(28, 48)
35 4.43 (3.13-6.26)
5 years
(26, 45)
N = 100 N = 100
61 11 (8.12-15)
21 months
(51, 71)
C 68 16 (11-25)
3 years
(58, 77)
64 14 (8.83-24)
5 years
(54, 73)
N = 99 N = 99
86 18 (14-25)
21 months
(77, 92)
W-135 85 31 (21-46)
3 years
(76, 91)
85 32 (21-47)
5 years
(76, 91)
N = 100 N = 100
71 14 (10-19)
21 months
(61, 80)
Y 69 14 (9.68-20)
3 years
(59, 78)
67 13 (8.8-20)
5 years
(57, 76)A booster dose of Menveo was administered 3 years after primary vaccination with Menveo or ACWY-D. Both groups showed a robust response to the booster dose of Menveo at one month after vaccination (100% of subjects had hSBA ≥ 1:8 across serogroups) and this response largely persisted through 2 years after the booster dose for serogroups C, W-135 and Y (with 87% to 100% of subjects with hSBA ≥ 1:8 across serogroups). A small decline was observed in percentages of subjects with hSBA ≥ 1:8 against serogroup A, although percentages were still high (77% to 79%). GMTs declined over time as expected but remained between 2- and 8-fold higher than prebooster values (Table 10).
In study V59P6E1, at one year post vaccination, the percentage of Menveo recipients with hSBA ≥ 1:8 remained significantly higher compared with ACWY-PS recipients for serogroups C, W-135 and Y, and similar between the two study groups for serogroup A. hSBA GMTs for serogroups W-135 and Y were higher among Menveo recipients. In 5 years post vaccination, the percentage of Menveo recipients with hSBA ≥ 1:8 remained significantly higher compared with ACWY-PS recipients for serogroups C and Y. Higher hSBA GMTs were observed for serogroups W-135 and Y (Table 9).
Table 9: Persistence of immune responses approximately 12 months and 5 years after vaccination with Menveo and ACWY-PS (subjects were aged 11-18 years at the time of vaccination)
Percentages of subjects with
hSBA GMTs
hSBA ≥ 1:8
P Value P Value
Serogroup Timepoint Menveo Menveo
ACWY-
Menveo vs Menveo ACWY-PS vs
PS
ACWY- ACWY-
PS PS
N = 50 N = 50 N = 50 N = 50
5.19
41% 43% 6.19
12 months 0.73 (3.34, 8.09 0.54
(27, 56) (28, 59) (3.96, 9.66)
A )
5.38
30% 44% 7.75
5 years 0.15 (3.29, 8.78 0.24
(18, 45) (30, 59) (4.83, 12)
)
N = 50 N = 50 N = 50 N = 50
82% 52% 29 17
12 months <0.001 0.22
C (68, 91) (37, 68) (15, 57) (8.55, 33)
76% 62% 21 20
5 years 0.042 0.92
(62, 87) (47, 75) (12, 37) (12, 35)
N = 50 N = 50 N = 50 N = 50
92% 52% 41 10
12 months <0.001 <0.001
W-135 (80, 98) (37, 68) (26, 64) (6.41, 16)
72% 56% 30 13
5 years 0.093 0.012
(58, 84) (41, 70) (18, 52) (7.65, 22)
N = 50 N = 50 N = 50 N = 50
78% 50% 34 9.28
12 months 0.001 <0.001
Y (63, 88) (35, 65) (20, 57) (5.5, 16)
76% 50% 30 8.25
5 years 0.002 <0.001
(62, 87) (36, 64) (18, 49) (5.03, 14)A booster dose of Menveo was administered 5 years after primary vaccination with Menveo or ACWY-PS. At 7 days after the booster dose, 98%-100% of subjects who previously received Menveo and 73%-84% of subjects who previously received ACWY-PS achieved hSBA ≥ 1:8 against serogroups A, C, W-135 and Y. At one month post vaccination, the percentages of subjects with hSBA ≥ 1:8 were 98%-100% and 84%-96%, respectively.
A significant increase in the hSBA GMTs against all four serogroups was also observed at 7 and 28 days after the booster dose (Table 10).
Table 10: Response to Booster: bactericidal antibody responses to Menveo booster administered at 3 or 5 years after the primary vaccination with Menveo or ACWY-PS in subjects aged 11-17 years
Percentages of subjects with
hSBA GMTs
hSBA ≥ 1:8
V59P13E
V59P13E1
V59P6E1 (3 years V59P6E1
Serog Time (3 years
(5 years post post (5 years post
roup point post
vaccination) vaccinatio vaccination)
vaccinati
n)
on)
ACWY- ACWY-
Menveo Menveo Menveo Menveo
PS PS
N = 42 N = 49 N = 49 N = 42 N = 49 N = 49
Pre-boo 21% 29% 43% 2.69 5.16 7.31
ster (10, 37) (17, 43) (29, 58) (1.68, 4.31) (3.46, 7.7) (4.94, 11)
100% 73% 1 059 45
7 days - -
A (93, 100) (59, 85) (585, 1 917) (25, 80)
100% 98% 94% 326 819 147
28 days
(92, 100) (89, 100) (83, 99) (215, 494) (514, 1305) (94, 232)
79% 22
2 years - - - -
(63, 90) (12, 41)
N = 42 N = 49 N = 49 N = 42 N = 49 N = 49
Pre-boo 55% 78% 61% 16 20 19
ster (39, 70) (63, 88) (46, 75) (8.66, 31) (13, 33) (12, 31)
100% 78% 1 603 36
7 days - -
(93, 100) (63, 88) (893, 2 877) (20, 64)
C
100% 100% 84% 1 217 51
28 days (352, 1 014
(92, 100) (93, 100) (70, 93) (717, 2 066) (30, 86)
)
95% 124
2 years - - - -
(84, 99) (62, 250)
N = 41 N = 49 N = 49 N = 41 N = 49 N = 49
Pre-boo 88% 73% 55% 37 29 12
ster (74, 96) (59, 85) (40, 69) (21, 65) (17, 49) (7.02, 19)
1 685
100% 84% 34
7 days - - (1 042, 2 725
(93, 100) (70, 93) (21, 54)
W-135 )
673 1 644
100% 100% 92% 47
28 days (398, 1 137 (1 090, 2 481
(91, 100) (93, 100) (80, 98) (32, 71)
) )
100% 93
2 years - - -
(91, 100) (58, 148)
N = 42 N = 49 N = 49 N = 42 N = 49 N = 49
Pre-boo 74% 78% 51% 14 28 7.8
ster (58, 86) (63, 88) (36, 66) (8.15, 26) (18, 45) (4.91, 12)
2 561
98% 76% 21
7 days - - (1 526, 4 298
(89, 100) (61, 87) (13, 35)
Y )
2 092
100% 100% 96% 532 63
28 days (1 340, 3 268
(92, 100) (93, 100) (86, 100) (300, 942) (41, 98)
)
95% 55
2 years - - - -
(84, 99) (30, 101)Immunogenicity in adults
In the pivotal immunogenicity trial, V59P13, immune responses to Menveo were assessed among adults aged 19 to 55 years. Results are presented in Table 11. In the subset of subjects aged 19-55 years who were seronegative at baseline, the proportion of subjects who achieved a hSBA ≥ 1:8 after a dose of Menveo were as follows: serogroup A 67% (582/875); serogroup C 71% (401/563); serogroup W-135 82% (131/160); serogroup Y 66% (173/263).
Table 11: Serum bactericidal antibody responses following Menveo one month after vaccination among subjects aged 19-55 years
GMT hSBA ≥ 1:8
Serogroup N
(95% CI) (95% CI)
A 963 31 (27, 36) 69% (66, 72)
C 902 50 (43, 59) 80% (77, 83)
W-135 484 111 (93, 132) 94% (91, 96)
Y 503 44 (37, 52) 79% (76, 83)The onset of immune response after the primary vaccination with Menveo in healthy subjects 18 through 22 years of age was evaluated in study V59P6E1. At 7 days post vaccination, 64% of subjects achieved hSBA ≥ 1:8 against serogroup A and 88% through 90% of subjects had bactericidal antibodies against serogroups C, W-135 and Y. At one month post vaccination, 92% through 98% of subjects had hSBA ≥ 1:8 against serogroups A, C, W-135 and Y. A robust immune response as measured by hSBA GMTs against all serogroups was also observed at 7 days (GMTs 34 through 70) and 28 days (GMTs 79 through 127) after a single dose vaccination.
Immunogenicity in older adults (aged 56-65 years)
The comparative immunogenicity of Menveo vs. ACWY-PS was evaluated in subjects aged 56-65 years, in study V59P17. The proportion of subjects with hSBA ≥ 1:8 was non-inferior to ACWY-PS for all four serogroups and statistically superior for serogroups A and Y (Table 12).
Table 12: Immunogenicity of one dose of Menveo or ACWY-PS in adults aged 56-65 years, measured at one month post vaccination.
Menveo ACWY-PS
Serogroup hSBA ≥ 1:8 hSBA ≥ 1:8
(95% CI) (95% CI)
N = 83 N = 41
A 87% 63%
(78, 93) (47, 78)
N = 84 N = 41
C 90% 83%
(82, 96) (68, 93)
N = 82 N = 39
W-135 94% 95%
(86, 98) (83, 99)
N = 84 N = 41
Y 88% 68%
(79, 94) (52, 82)Available data in children 2 to 23 months of age
The immunogenicity of Menveo in children 2 to 23 months of age was evaluated in several studies. Although a high percentage of subjects achieved hSBA titers above 1:8 following 4-dose series of Menveo, with lower percentages in studies of 2-dose series and of a single dose, Menveo was
compared to another meningococcal vaccine in only one pivotal study, where it failed to show a response at least equivalent to a monovalent conjugated serotype C vaccine (after a single dose at the age of 12 months). Currently available data are not sufficient to establish the efficacy of Menveo in children under 2 years of age. See section 4.2 for information on paediatric use.
Pharmacokinetics
SmPC 5.2 Pharmacokinetic properties EU SmPC (EMA)
Not applicable.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- European Medicines Agency. Menveo: EPAR, product information, Annex I, Summary of Product Characteristics [EU SmPC, last updated October 14, 2025; no US FDA label]. https://www.ema.europa.eu/en/medicines/human/EPAR/menveo © European Medicines Agency; reproduced with acknowledgment of the source.
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .